423 related articles for article (PubMed ID: 23140947)
1. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Doi A; Shimada T; Harada S; Iwata K; Kamiya T
Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
[TBL] [Abstract][Full Text] [Related]
2. Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.
Araki K; Fukuoka K; Higuchi H; Aizawa Y; Horikoshi Y
Pediatr Int; 2019 Jun; 61(6):572-577. PubMed ID: 30908807
[TBL] [Abstract][Full Text] [Related]
3. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Asakura T; Ikeda M; Nakamura A; Kodera S
Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
[TBL] [Abstract][Full Text] [Related]
5. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
6. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in children.
Katsuta T; Shoji K; Watanabe Y; Saitoh A
Pediatr Infect Dis J; 2013 Apr; 32(4):417-9. PubMed ID: 23274920
[TBL] [Abstract][Full Text] [Related]
9. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
[TBL] [Abstract][Full Text] [Related]
10. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Harada S; Ishii Y; Yamaguchi K
Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
[TBL] [Abstract][Full Text] [Related]
11. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
Kim SA; Altshuler J; Paris D; Fedorenko M
Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.
Matsumura Y; Yamamoto M; Nagao M; Tanaka M; Takakura S; Ichiyama S
Diagn Microbiol Infect Dis; 2016 Apr; 84(4):322-7. PubMed ID: 26782634
[TBL] [Abstract][Full Text] [Related]
13. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
14. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
15. [Extended-spectrum beta-lactamase producing-enterobacteriaceae].
Mariani-Kurkdjian P; Doit C; Bingen E
Arch Pediatr; 2012 Nov; 19 Suppl 3():S93-6. PubMed ID: 23178141
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
Bindayna KM; Senok AC; Jamsheer AE
J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
[TBL] [Abstract][Full Text] [Related]
17. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
19. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
